Etoposide
- Generic Name
- Etoposide
- Brand Names
- Etopophos, Toposar, Vepesid
- Drug Type
- Small Molecule
- Chemical Formula
- C29H32O13
- CAS Number
- 33419-42-0
- Unique Ingredient Identifier
- 6PLQ3CP4P3
- Background
A semisynthetic derivative of podophyllotoxin that exhibits antitumor activity. Etoposide inhibits DNA synthesis by forming a complex with topoisomerase II and DNA. This complex induces breaks in double stranded DNA and prevents repair by topoisomerase II binding. Accumulated breaks in DNA prevent entry into the mitotic phase of cell division, and lead to cell death. Etoposide acts primarily in the G2 and S phases of the cell cycle.
- Indication
For use in combination with other chemotherapeutic agents in the treatment of refractory testicular tumors and as first line treatment in patients with small cell lung cancer. Also used to treat other malignancies such as lymphoma, non-lymphocytic leukemia, and glioblastoma multiforme.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Myeloid Leukemia, Advanced Hodgkin's Lymphoma, Ewing's Sarcoma, Gestational Trophoblastic Neoplasia, Merkel cell cancer, Multiple Myeloma (MM), Neuroblastoma (NB), Neuroendocrine Tumors, Non-Hodgkin's Lymphomas, Non-Small Cell Lung Cancer (NSCLC), Osteosarcoma, Ovarian Cancer, Prostate Cancer, Retinoblastoma, Small Cell Lung Cancer (SCLC), Wilms' tumor, Locally advanced Thymoma, Metastatic Thymic Cancer, Refractory Sarcoma, Refractory Testicular cancer
- Associated Therapies
- -
Nelfinavir, Radiation Therapy, Cisplatin, and Etoposide in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery
- Conditions
- Lung Cancer
- Interventions
- Drug: cisplatinDrug: etoposideDrug: nelfinavir mesylateGenetic: protein expression analysisOther: immunohistochemistry staining methodOther: laboratory biomarker analysisProcedure: biopsyRadiation: radiation therapy
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Abramson Cancer Center at Penn Medicine
- Target Recruit Count
- 55
- Registration Number
- NCT00589056
- Locations
- 🇺🇸
Abramson Cancer Center of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer
- Conditions
- Chronic Myeloproliferative DisordersGraft Versus Host DiseaseInfectionLeukemiaLymphomaMultiple Myeloma and Plasma Cell NeoplasmMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative NeoplasmsPrecancerous ConditionSecondary Myelofibrosis
- Interventions
- Biological: anti-thymocyte globulinDrug: fludarabine phosphateDrug: cyclophosphamideDrug: etoposideDrug: melphalanDrug: sirolimusDrug: methotrexateDrug: tacrolimusProcedure: allogeneic hematopoietic stem cell transplantationProcedure: hematopoietic stem cell transplantationProcedure: nonmyeloablative allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: total-body irradiation
- First Posted Date
- 2008-01-09
- Last Posted Date
- 2014-09-10
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 32
- Registration Number
- NCT00589563
- Locations
- 🇺🇸
City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Banner Good Samaritan Medical Center, Phoenix, Arizona, United States
Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
- Conditions
- Lymphoma, B-Cell
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2017-05-30
- Lead Sponsor
- Duke University
- Target Recruit Count
- 39
- Registration Number
- NCT00577629
- Locations
- 🇺🇸
Duke University Medical Center, Durham, North Carolina, United States
Fludarabine, Mitoxantrone, and Dexamethasone (FND) Plus Rituximab for Lymphoma Patients
- Conditions
- Lymphoma
- Interventions
- First Posted Date
- 2007-12-20
- Last Posted Date
- 2020-11-16
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 210
- Registration Number
- NCT00577993
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Intensity-Modulated Radiation Therapy, Etoposide, and Cyclophosphamide Followed By Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia
- Conditions
- Leukemia
- Interventions
- Drug: cyclophosphamideDrug: etoposideProcedure: allogeneic bone marrow transplantationProcedure: allogeneic hematopoietic stem cell transplantationProcedure: peripheral blood stem cell transplantationRadiation: intensity-modulated radiation therapyRadiation: tomotherapy
- First Posted Date
- 2007-12-19
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 51
- Registration Number
- NCT00576979
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2007-12-14
- Last Posted Date
- 2012-04-24
- Lead Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Target Recruit Count
- 31
- Registration Number
- NCT00573690
- Locations
- 🇺🇸
Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill, North Carolina, United States
UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy
- Conditions
- Multiple Myeloma
- Interventions
- First Posted Date
- 2007-12-12
- Last Posted Date
- 2024-04-10
- Lead Sponsor
- University of Arkansas
- Target Recruit Count
- 177
- Registration Number
- NCT00572169
- Locations
- 🇺🇸
University of Arkansas for Medical Sciences/Myeloma Institute, Little Rock, Arkansas, United States
Gene Therapy-Treated Stem Cells in Treating Patients Undergoing Stem Cell Transplant for Intermediate-Grade or High-Grade AIDS-Related Lymphoma
- Conditions
- Lymphoma
- Interventions
- Biological: lentivirus vector rHIV7-shI-TAR-CCR5RZ-transduced hematopoietic progenitor cellsDrug: carmustineDrug: cyclophosphamideDrug: etoposideProcedure: autologous hematopoietic stem cell transplantation
- First Posted Date
- 2007-12-10
- Last Posted Date
- 2019-11-15
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 5
- Registration Number
- NCT00569985
- Locations
- 🇺🇸
City of Hope Medical Center, Duarte, California, United States
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma
- Conditions
- Localized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaRecurrent NeuroblastomaRegional NeuroblastomaStage 4 NeuroblastomaStage 4S Neuroblastoma
- Interventions
- Procedure: Autologous Hematopoietic Stem Cell TransplantationDrug: CarboplatinDrug: CisplatinDrug: CyclophosphamideDrug: Doxorubicin HydrochlorideDrug: EtoposideRadiation: External Beam Radiation TherapyBiological: FilgrastimDrug: IsotretinoinOther: Laboratory Biomarker AnalysisDrug: MelphalanProcedure: Peripheral Blood Stem Cell TransplantationOther: Pharmacological StudyDrug: Topotecan HydrochlorideDrug: ThiotepaDrug: Vincristine Sulfate Liposome
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 665
- Registration Number
- NCT00567567
- Locations
- 🇺🇸
Cedars Sinai Medical Center, Los Angeles, California, United States
🇺🇸Valley Children's Hospital, Madera, California, United States
🇺🇸Children's Healthcare of Atlanta - Egleston, Atlanta, Georgia, United States
Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
- Conditions
- Lymphoma
- Interventions
- Biological: filgrastimDrug: cyclophosphamideDrug: etoposideProcedure: AHSCTRadiation: yttrium Y 90 ibritumomab tiuxetan
- First Posted Date
- 2007-11-26
- Last Posted Date
- 2021-06-18
- Lead Sponsor
- City of Hope Medical Center
- Target Recruit Count
- 54
- Registration Number
- NCT00562978
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.